EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HLB Therapeutics Co's enterprise value is ₩561,698 Mil.
HLB Therapeutics Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩56,234 Mil. Therefore, HLB Therapeutics Co's EV-to-Revenue for today is 9.99.
The historical rank and industry rank for HLB Therapeutics Co's EV-to-Revenue or its related term are showing as below:
XKRX:115450'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.68 Med: 11.74 Max: 80.45
Current: 9.98
During the past 13 years, the highest EV-to-Revenue of HLB Therapeutics Co was 80.45. The lowest was 0.68. And the median was 11.74.
XKRX:115450's EV-to-Revenue is ranked worse than 55.49% of 1038
companies
in the Biotechnology industry
Industry Median: 8.075
vs XKRX:115450: 9.98
The historical data trend for HLB Therapeutics Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HLB Therapeutics Co's EV-to-Revenue
For the Biotechnology subindustry, HLB Therapeutics Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLB Therapeutics Co's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where HLB Therapeutics Co's EV-to-Revenue falls into.
HLB Therapeutics Co's current Enterprise Value is ₩561,698 Mil.
HLB Therapeutics Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩56,234 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLB Therapeutics Co (XKRX:115450) EV-to-Revenue Explanation
HLB Therapeutics Co's share price for today is ₩7630.00.
HLB Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩790.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLB Therapeutics Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of HLB Therapeutics Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
HLB Therapeutics Co (XKRX:115450) Business Description
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:115450 has been successfully added to your 